Letter to the Editor

Adverse effects of ethyl esters or oxidation products in omega-3 preparations?

Dear Sir

We read with interest the article by Opperman and Benade, titled “Analysis of the omega-3 fatty acid content of South African fish oil supplements: a follow-up study.” We make the following comments.

In humans, long-chain omega-3 fatty acids are required in numerous cellular mechanisms and are converted in small amounts from the plant-based precursor alpha-linolenic acid. It therefore seemed paradoxical when we found that in patients with dilative heart failure, the blood levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were reduced.2-3 We concluded that a deficiency in highly unsaturated fatty acids (HUFA) represents a key defect contributing to the rapid progression of heart failure requiring replacement therapy.4 It is therefore important to assess whether dietary supplement and pharmaceutical-grade omega-3 preparations vary not only in environmental pollutants, but also in adverse oxidation products.

Opperman and Benade1 assessed differences in dietary supplement fish oils available on the South African market. Compared with their 2009 survey, almost a third of the supplements contained ethyl esters (EEs), which appeared to be associated with higher EPA and DHA levels. Although we share their contention that the presence of EEs should be declared on the supplement label, we do not see the evidence for their statement that the safety of a daily intake of EEs has not been confirmed in humans.

In a major prospective, randomised clinical trial by the Gissi-HF investigators,6 EPA/DHA was administered as EEs in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–1230.

According to our recent study on 63 dietary supplement fish oils from 13 countries,7 the omega-3 fatty acid content varied significantly. In this context it is important to note that the ingestion of less oxidised omega-3 supplements reduced circulating triglyceride and cholesterol levels, as opposed to highly oxidised omega-3 capsules, which had a negative effect on cholesterol levels.8,9

In view of the increasing evidence that the oxidation level of omega-3 fatty acid supplements can be a health risk, we consider it timely to change the perception that EPA/DHA is beneficial, irrespective of the source and the presence of oxidation products. Of particular concern is that the majority of fish oils exhibit a peroxide content above the recommended level of the Global Organisation for EPA and DHA Omega-3 (GOED), i.e. > 80% (South African market, photometric method),10 89% (market of 13 countries, photometric method),11 and 93% (Norwegian market, AOCS official method).11

Heinz Rupp, Rupp@uni-marburg.de
Karin G Rupp, kg.rupp@gmx.de
Experimental Cardiology Laboratory, Department of Internal Medicine – Cardiology, Philipps University, Marburg, Germany

References

1. Opperman M, Benade S. Analysis of the omega-3 fatty acid content of South African fish oil supplements: a follow-up study. Cardiovasc J Afr 2013; 24: 297–302.

2. Rupp H, Rupp TP, Alter P, Maisch B. N-3 polyunsaturated fatty acids and statins in heart failure. Lancet 2009; 373: 378–379.

3. Rupp H, Rupp TP, Alter P, Maisch B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart 2010; 96: 595–598.

4. Rupp H, Rupp TP, Alter P, Maisch B. Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in “HUFA deficiency”. Can J Physiol Pharmacol 2012; 90: 55–73.

5. Bourdon JA, Bazinet TM, Arnason TT, Kimpe LE, Blais JM, White PA. Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of omega-3 polyunsaturated fatty acid supplements: implications for daily intake of dioxins and PCBs. Food Chem Toxicol 2010; 48: 3093–3097.

6. Gissi-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–1230.

7. GISSI-Prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354: 447–455.

8. Luley C, Wieland H, Grünwald J. Bioavailability of omega-3 fatty acids: ethylester preparations are as suitable as triglyceride prepara-
tions. Akt Ernähr Med 1990; 15: 123–125.

9. Rupp TP, Rupp KG, Alter P, Rupp H. Replacement of reduced highly unsaturated fatty acids (HUFA deficiency) in dilative heart failure: dosage of EPA/DHA and variability of adverse peroxides and aldehydes in dietary supplement fish oils. Cardiology 2013; 125: 223–231.

10. Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, Micol V, Roche E, Garcia-Garcia E. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int J Food Sci Nutr 2013; 64: 993–1000.

11. Ruyter B, Grimmer S, Thorkildsen T, Todorcevic M, Lalic M. Lite Oksiderte Omega-3 Oljer og Potensielle Helsefordele. Trondheim: Rubin, 2010; 196: 1–60.

The 8th Annual Meeting of the National Scholarly Editors’ Forum of South Africa

Wednesday 30 July 2014

Venue: Belmont Square Conference Centre, Rondebosch, Cape Town

We are pleased to announce that the 8th annual meeting of the National Scholarly Editors’ Forum of South Africa will be held at the Belmont Square Conference Centre, Rondebosch, Cape Town on Wednesday 30 July 2014 from 10:00–16:30.

The annual meeting is an opportunity for journal editors to exchange information and knowledge in our field. It is also an exceptional occasion to meet not only our disciplinary peers, but other experts who share the same interests.

The ad hoc organising committee will draft the preliminary agenda and if you have any agenda items for discussion, please submit such items to me, Gugulethu (Gugulethu@assaf.org.za). In addition, if there are specific articles, research or reports that you would like to share with editors at this meeting, please send them to me as well.

Please note that there are limited travel grants available. Please submit a motivation to me on Gugulethu@assaf.org.za.

If you seek clarity on any NSEF-related matter, please contact Mrs Susan Veldsman at ASSAf on susan@assaf.org.za or 012 349-6611.